To further investigate the role of EGFR in the acquired resistance of HCC to regorafenib, we performed various in vitro and in vivo experiments to determine whether EGFR inhibition by gefitinib could restore regorafenib sensitivity in HCC. Here, EGFR is linked to hepatocellular carcinoma.